A detailed history of Southpoint Capital Advisors LP transactions in Tango Therapeutics, Inc. stock. As of the latest transaction made, Southpoint Capital Advisors LP holds 5,276,699 shares of TNGX stock, worth $39.4 Million. This represents 1.32% of its overall portfolio holdings.

Number of Shares
5,276,699
Previous 5,276,699 -0.0%
Holding current value
$39.4 Million
Previous $41.9 Million 8.06%
% of portfolio
1.32%
Previous 0.95%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$6.52 - $12.01 $5.06 Million - $9.33 Million
776,699 Added 17.26%
5,276,699 $52.2 Million
Q2 2022

Aug 15, 2022

BUY
$3.86 - $8.01 $2.68 Million - $5.56 Million
694,071 Added 18.24%
4,500,000 $20.4 Million
Q1 2022

May 16, 2022

BUY
$7.01 - $10.94 $5.65 Million - $8.82 Million
805,929 Added 26.86%
3,805,929 $28.8 Million
Q3 2021

Nov 15, 2021

BUY
$9.56 - $17.3 $28.7 Million - $51.9 Million
3,000,000 New
3,000,000 $38.8 Million

Others Institutions Holding TNGX

About Tango Therapeutics, Inc.


  • Ticker TNGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 88,067,296
  • Market Cap $658M
  • Description
  • Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops...
More about TNGX
Track This Portfolio

Track Southpoint Capital Advisors LP Portfolio

Follow Southpoint Capital Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Southpoint Capital Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Southpoint Capital Advisors LP with notifications on news.